Xnovis Completes Hundreds of Millions RMB Pre-IPO Financing Round to Advance Global Clinical Trials and Manufacturing Facility

VCBeat (WeChat ID: vcbeat) has learned that in December 2020, Suzhou Evopoint Biosciences Co., Ltd. (“Evopoint”) successfully completed a Pre-IPO financing round amounting to hundreds of millions of RMB. The round was led by Haisong Capital, with participation from several renowned institutions, including CDIB Venture Capital, Jiuyou Capital, Fengyi Yuanda Capital, ABC International, and Deguan Capital. Xingyuan Zhitong served as the exclusive financial advisor for this financing round.

Evopoint Biosciences, founded in 2017, is an innovative pharmaceutical company focused on addressing major unmet clinical needs and holding global intellectual property rights. Leveraging its Suzhou headquarters, the company has established four branch offices in Beijing, Shanghai, Australia, and Boston. It has received numerous prestigious awards and recognitions, including inclusion in the Suzhou Unicorn Cultivation Enterprise list, selection for the Jiangsu Province Double Innovation Plan, and designation as a Gusu Leading Talent.

Evopoint Biosciences focuses on addressing major unmet clinical needs globally, with a balanced pipeline strategy centered on next-generation Best-in-Class and First-in-Class assets. Its R&D portfolio spans oncology, antibiotics, autoimmune diseases, and metabolic disorders. Currently, five products have entered clinical trials domestically and internationally, while three are in the IND-enabling stage. The funds raised in this round will be primarily used to advance domestic and international clinical trials and construct manufacturing facilities, accelerating product commercialization to benefit a broad patient population.

Mr. Qiang Jing, Chairman of the Company, stated that Evopoint Biosciences has carefully considered unmet clinical needs and differentiated advantages over similar products in its product line layout, while balancing R&D success rates and commercial value. In the future, Evopoint Biosciences will honor its commitments and remain true to its original mission. Construction has commenced on the new pharmaceutical base, which will serve as the production and operational hub for Evopoint’s innovative drug formulations. The completion of this new base marks not only a new beginning but also an opportunity to attract more high-end pharmaceutical R&D talent to the industrial park, further promoting and enhancing the development, industrial upgrading, and international competitiveness of the biopharmaceutical sector within the park, thereby contributing to the establishment of a trillion-level biopharmaceutical manufacturing hub. The company has established a robust team structure staffed with top-tier industry professionals, continuously focusing on major therapeutic areas such as oncology and anti-infectives, enriching its product pipeline, and striving to provide patients with more high-quality medicines.

Evopoint Biosciences Base Rendering

As the lead investor in this round, Mr. Chen Liguang, Founder of Haisong Capital, stated: “Evopoint Biosciences is a startup dedicated to the development of innovative drugs worldwide. Its drug R&D portfolio covers multiple therapeutic areas, including oncology, autoimmune diseases, and infectious diseases, demonstrating remarkable efficacy and unique competitive advantages that address urgent unmet clinical needs in these fields. The company’s founding team possesses extensive entrepreneurial experience as well as expertise in drug R&D and commercialization. We are highly optimistic about Evopoint Biosciences’ founding team and its product pipeline. It is our great honor to continue supporting Evopoint Biosciences in this funding round, and we are delighted to grow alongside the company. This financing will accelerate Evopoint Biosciences’ journey toward becoming a highly competitive pharmaceutical enterprise on a global scale.”

Mr. Fu Jia, Managing Director of Xingyuan Zhitong, stated, “We are honored to partner once again with Evopoint Biosciences in facilitating the company’s Pre-IPO financing round. Since the completion of its Series C funding, Evopoint Biosciences has achieved a series of above-expectation milestones in R&D, clinical development, and team building, steadily advancing toward becoming a leading Big Pharma enterprise in China and globally. Xingyuan Zhitong sincerely wishes Evopoint Biosciences further growth through the capital markets, bringing more urgently needed innovative and high-quality medicines to patients worldwide.”

Suzhou Evopoint Biosciences Co., Ltd. was founded in 2017 as an innovative pharmaceutical company focused on addressing major unmet clinical needs and holding global intellectual property rights. Evopoint has strategically positioned itself along two dimensions: developing Best-in-Class products targeting established pathways and First-in-Class products targeting novel pathways. Currently, five of its drug candidates have entered clinical trials both domestically and internationally, with three additional candidates in the IND-enabling stage, covering key therapeutic areas including oncology, anti-infectives, metabolism, and autoimmune diseases.